¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼ú ½ÃÀå
Mammalian Cell Fermentation Technology
»óǰÄÚµå : 1775001
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 392 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼ú ½ÃÀåÀº 2030³â±îÁö 707¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 452¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼ú ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 7.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 707¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áß±¹ ÇܽºÅÍ ³­¼Ò ¼¼Æ÷ ¹ßÈ¿´Â CAGR 9.7%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 326¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àΰ£ ¹è¼º ½ÅÀå ¼¼Æ÷ ¹ßÈ¿ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 5.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 123¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼ú ½ÃÀåÀº 2024³â¿¡ 123¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 153¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.7%¿Í 7.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼úÀÇ Á߿伺ÀÌ Ä¿Áö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼úÀº Ä¡·á¿ë ´Ü¹éÁú, ´ÜŬ·Ð Ç×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÇ ´ë·® »ý»êÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¹ÙÀÌ¿À Á¦¾à »ê¾÷¿¡¼­ Áß¿äÇÑ ±¸¼º ¿ä¼ÒÀÔ´Ï´Ù. ¹ÚÅ׸®¾Æ³ª È¿¸ð ±â¹Ý ¹ßÈ¿¿Í ´Þ¸® Æ÷À¯·ù ¼¼Æ÷ ½Ã½ºÅÛÀº º¹ÀâÇÑ ¹ø¿ª ÈÄ º¯ÇüÀÌ °¡´ÉÇÏ¿© »ý¹°ÇÐÀûÀ¸·Î Ȱ¼ºÀûÀ̰í Àΰ£¿¡ ÀûÇÕÇÑ ´Ü¹éÁúÀ» »ý»êÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦, ¸ÂÃãÀÇ·á, Àç»ýÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¾Ï, ÀÚ°¡¸é¿ªÁúȯ, Èñ±ÍÀ¯ÀüÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¹ÙÀÌ¿ÀÀǾàǰ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»ç ¹× À§Å¹»ý»ê ±â°üÀº ÀǾàǰ °³¹ßÀ» °¡¼ÓÈ­ÇÏ°í »ý»ê È¿À²¼ºÀ» ³ôÀÌ¸ç ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ Æ÷À¯·ù ¼¼Æ÷ ¹è¾ç ½Ã½ºÅÛÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼úÀÇ ¼º´ÉÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ, ¿¬¼Ó »ý»ê ½Ã½ºÅÛ, ÀΰøÁö´ÉÀ» ÅëÇÑ °øÁ¤ ÃÖÀûÈ­ÀÇ ¹ßÀüÀº Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ½Ã½ºÅÛÀº ¿À¿° À§ÇèÀ» ÁÙÀ̰í, ¿î¿µ ºñ¿ëÀ» ³·Ã߸ç, È®À强À» Çâ»ó½Ã۱⠶§¹®¿¡ ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶¾÷ü¿¡°Ô ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ ÆíÁý ±â¼ú ¹× ÇÕ¼º »ý¹°ÇÐÀÇ ¹ßÀüÀ¸·Î ¼¼Æ÷ÁÖ °øÇÐÀÌ °­È­µÇ¾î º¸´Ù ºü¸£°í È¿À²ÀûÀÎ ´Ü¹éÁú ¹ßÇöÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

ÀÚµ¿È­¿Í µ¥ÀÌÅÍ ºÐ¼®Àº ¹ßÈ¿ Á¶°ÇÀ» ÃÖÀûÈ­Çϰí, º¯µ¿À» ÃÖ¼ÒÈ­Çϸç, ÀϰüµÈ Á¦Ç° ǰÁúÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ÅëÇյǰí ÀÖÀ¸¸ç, ¼öÀ²°ú È¿À²¼ºÀ» ±Ø´ëÈ­Çϱâ À§ÇØ ¿¹Ãø À¯Áö º¸¼ö ¹× ÀûÀÀÇü °øÁ¤ Á¦¾î¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº?

»ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·áÁ¦, ¼¼Æ÷ ±â¹Ý ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Á¤ºÎ ¹× ±ÔÁ¦ ±â°üÀº ½Å¼ÓÇÑ ½ÂÀΰú ÆÒµ¥¹Í ´ëÀÀÀ» À§ÇÑ ÀÚ±Ý Áö¿øÀ» ÅëÇØ »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ÀÇ È®´ë¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í Â÷¼¼´ë Ç×ü Ä¡·áÁ¦ÀÇ ºÎ»óµµ ºñ¿ë È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ Æ÷À¯·ù ¼¼Æ÷ ¹è¾ç ±â¼úÀÇ Çʿ伺À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀüÀ¸·Î ȯÀÚ °³°³Àο¡ ¸Â´Â ¸ÂÃãÇü ¼¼Æ÷ÁÖ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÌ ºñ¿ë Àý°¨°ú Á¦Ç°È­ ½Ã°£ ´ÜÃàÀ» À§ÇØ Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿¸¦ Àü¹® ¾÷ü¿¡ À§Å¹ÇÔ¿¡ µû¶ó À§Å¹ °³¹ß ¹× Á¦Á¶ ±â°ü ºÎ¹®Àº °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦Á¶ÀÇ Áö¼Ó°¡´É¼º¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ģȯ°æ ¼¼Æ÷ ¹è¾ç ¹èÁö ¹× ¿¡³ÊÁö È¿À²ÀÌ ³ôÀº ¹ßÈ¿ ±â¼úÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù.

¾î¶² °úÁ¦¿Í ¹Ì·¡ ±âȸ°¡ Á¸ÀçÇÒ±î?

Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ÀÇ °úÁ¦´Â ³ôÀº »ý»ê ºñ¿ë, º¹ÀâÇÑ ±ÔÁ¦ ¿ä°Ç, ±âÁ¸ ¹èÄ¡ °øÁ¤ÀÇ È®À强 ÇÑ°è µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¼¼Æ÷ÀÇ »ýÁ¸¼ºÀ» À¯ÁöÇϰí Áõ½Ä Á¶°ÇÀ» ÃÖÀûÈ­ÇÏ´Â °ÍÀº ¿©ÀüÈ÷ Áß¿äÇÑ ±â¼úÀû Àå¾Ö¹°ÀÔ´Ï´Ù. ±×·¯³ª ¿¬¼Ó°ü·ù ¹ÙÀÌ¿À¸®¾×ÅÍ, ÀΰøÁö´ÉÀ» ÅëÇÑ ¼¼Æ÷ ¹è¾ç ÃÖÀûÈ­, ÇÏÀ̺긮µå ¹ßÈ¿ ¸ðµ¨°ú °°Àº »õ·Î¿î ±â¼ú Çõ½ÅÀº ºñ¿ë È¿À²ÀûÀÌ°í ¼öÀ²ÀÌ ³ôÀº ¹ÙÀÌ¿ÀÀǾàǰ »ý»êÀÇ »õ·Î¿î ±âȸ¸¦ ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

°³ÀÎ ¸ÂÃãÇü ¼¼Æ÷Ä¡·á, ÀΰøÁö´É ±â¹Ý °øÁ¤ ÀÚµ¿È­, ¸ðµâÇü ¹ÙÀÌ¿À Á¦Á¶ ½Ã¼³ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, Æ÷À¯·ù ¼¼Æ÷ ¹ßÈ¿ ±â¼úÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(Áß±¹ ÇܽºÅÍ ³­¼Ò ¼¼Æ÷ ¹ßÈ¿, Àΰ£ ¹è¼º ½ÅÀå ¼¼Æ÷ ¹ßÈ¿, º£À̺ñ ÇܽºÅÍ ½ÅÀå ¼¼Æ÷ ¹ßÈ¿, ¸¶¿ì½º °ñ¼öÁ¾ ¼¼Æ÷ ¹ßÈ¿, ±âŸ À¯Çü), ¿ëµµ(´ÜÀÏŬ·ÐÇ×ü ¿ëµµ, ÀçÁ¶ÇÕ ´Ü¹éÁú ¿ëµµ, ¹é½Å ¿ëµµ, È£¸£¸ó ¿ëµµ, È¿¼Ò ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷ ÃÖÁ¾ ¿ëµµ, Çмú±â°ü ¹× ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Mammalian Cell Fermentation Technology Market to Reach US$70.7 Billion by 2030

The global market for Mammalian Cell Fermentation Technology estimated at US$45.2 Billion in the year 2024, is expected to reach US$70.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Chinese Hamster Ovary Cell Fermentation, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$32.6 Billion by the end of the analysis period. Growth in the Human Embryonic Kidney Cell Fermentation segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.3 Billion While China is Forecast to Grow at 12.4% CAGR

The Mammalian Cell Fermentation Technology market in the U.S. is estimated at US$12.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.3 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Mammalian Cell Fermentation Technology Market - Key Trends & Drivers Summarized

Why Is Mammalian Cell Fermentation Technology Gaining Importance?

Mammalian cell fermentation technology is a critical component in the biopharmaceutical industry, enabling the large-scale production of therapeutic proteins, monoclonal antibodies, vaccines, and gene therapy products. Unlike bacterial or yeast-based fermentation, mammalian cell systems allow for complex post-translational modifications, making them essential for producing biologically active and human-compatible proteins. As the demand for biologics, personalized medicine, and regenerative therapies continues to rise, the adoption of advanced mammalian cell fermentation technology is expanding.

The increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions is driving investments in biopharmaceutical research and development. Pharmaceutical companies and contract manufacturing organizations are leveraging mammalian cell culture systems to accelerate drug development, enhance production efficiency, and meet stringent regulatory standards.

How Are Innovations Enhancing the Performance of Mammalian Cell Fermentation Technology?

Advancements in single-use bioreactors, continuous manufacturing systems, and artificial intelligence-driven process optimization are revolutionizing mammalian cell fermentation. Single-use systems reduce contamination risks, lower operational costs, and improve scalability, making them a preferred choice for biopharmaceutical manufacturers. Additionally, developments in gene-editing techniques and synthetic biology are enhancing cell line engineering, enabling faster and more efficient protein expression.

Automation and data analytics are playing a significant role in optimizing fermentation conditions, minimizing variability, and ensuring consistent product quality. Artificial intelligence and machine learning algorithms are being integrated into real-time monitoring systems, allowing predictive maintenance and adaptive process control to maximize yield and efficiency.

What Are the Key Market Drivers?

The growing demand for biologic drugs, gene therapies, and cell-based vaccines is a primary driver for the mammalian cell fermentation market. Governments and regulatory agencies are supporting biologic manufacturing expansion through fast-track approvals and funding for pandemic preparedness. The rise of biosimilars and next-generation antibody therapies is also fueling the need for cost-effective and scalable mammalian cell culture technologies.

Additionally, advancements in personalized medicine are increasing the demand for customized cell lines tailored to individual patients. The contract development and manufacturing organization sector is witnessing significant growth as pharmaceutical companies outsource mammalian cell fermentation to specialized providers to reduce costs and accelerate time to market. The increasing focus on sustainability in biomanufacturing is also leading to the adoption of environmentally friendly cell culture media and energy-efficient fermentation technologies.

What Challenges and Future Opportunities Exist?

Challenges in mammalian cell fermentation include high production costs, complex regulatory requirements, and scalability limitations in traditional batch processes. Maintaining cell viability and optimizing growth conditions remain significant technical hurdles. However, emerging innovations in continuous perfusion bioreactors, artificial intelligence-assisted cell culture optimization, and hybrid fermentation models are opening new opportunities for cost-effective and high-yield biopharmaceutical production.

The increasing adoption of personalized cell therapies, artificial intelligence-driven process automation, and modular biomanufacturing facilities is expected to shape the future of mammalian cell fermentation technology.

SCOPE OF STUDY:

The report analyzes the Mammalian Cell Fermentation Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Chinese Hamster Ovary Cell Fermentation, Human Embryonic Kidney Cell Fermentation, Baby Hamster Kidney Cell Fermentation, Murine Myeloma Cell Fermentation, Other Types); Application (Monoclonal Antibodies Application, Recombinant Proteins Application, Vaccines Application, Hormones Application, Enzymes Application, Other Applications); End-Use (Biopharmaceutical Companies End-Use, Academic & Research Institutes End-Uses, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â